BEND, Ore.--(BUSINESS WIRE)--
Next generation sequencing services (NGSS)
identifying any plant pathogen
EVIO Inc. (âEVIOâ or
the âCompanyâ), (EVIO), a leading North
American provider of cannabis testing and scientific research for
the regulated cannabis industry, is excited to announce EVIO
Biosciences launches the release of the first Genomics Testing
program for Pathogen Identification in Cannabis. The EVIO Biosciences
division launched in May led by EVIOâs Chief Science Officer, Dr.
EVIO is proud to offer next generation DNA
sequencing services for pathogen surveillance in cannabis grow
operations. Next generation sequencing services (NGSS) genetically
identifies nearly all the microbial constituents in a particular
sample of plant tissue, soil or water. This service can help
producers identify plant pathogens contributing to loss of yield or
quality in your grow facility. NGSS can also be used to identify
workplace human pathogens to keep your workers safe. Perhaps more
important than pathogen ID, NGSS is a powerful tool for
establishing an understanding of beneficial microbial biome
constituents of your soil and cannabis plants. Knowing the
constituents of the microbial communities in your grow operations
can be the key to unlocking the effectiveness of your soil and
Our NGSS application performs iterative sequence
analysis of DNA that we isolate and prepare from environmental and
plant tissue samples in your operation. The samples we collect
contain hundreds or thousands of diverse microorganisms. NGSS is
based on sequence-based identification of 16S ribosomal RNA genes.
These genes encode an RNA molecule that are similarly conserved in
nearly all living cells. In a NGSS run, sections of this gene and
neighboring genetic regions are targeted to identify most present
DNA sequences to the genus of species level. This information helps
determine the presence and relative abundance of all microbial
community constituents in the sample.
Through cooperative sampling of roots, leaves,
and stem tissues, we can help to identify which beneficial and
plant pathogens are present, identify the source of pathogens, and
how manage their populations. We help to sample your healthy or
diseased plant tissues, take these backs to the lab, extract and
sequence the DNA in your samples. We interpret and report the
genomic information and put together a plan to help you move
forward and into the future.
Dr. Anthony Smith said, "We have achieved the
goal of leveraging NGSS technology to directly improve quality and
yield in Cannabis cultivation ops. Itâs a part of our mission, to
bring progressive technology applications into the cannabis sector,
and this technology has direct applicability to other markets such
as food safety, agriculture and water testing."
Dr. Anthony Smith received his PhD from Oregon
State University in Molecular & Cellular Biology with an
emphasis on biochemistry, metabolism and nutrition. He brings over
15 years of natural product research, quality assurance, product
development, GMP manufacturing, FDA & regulatory experience and
analytical expertise to EVIO.
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific
research for the regulated cannabis industry. The Companyâs EVIO
Labs division operates coast-to-coast providing state-mandated
ancillary services to ensure the safety and quality of the nation's
cannabis supply. The Companyâs EVIO Biosciences Division is
dedicated to the scientific, medical, and psychosocial exploration
of clinical cannabis, cannabinoids, and the endocannabinoid
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not statements of
historical fact maybe considered to be forward-looking statements.
Statements may contain certain forward-looking statements
pertaining to future anticipated or projected plans, performance
and developments, as well as other statements relating to future
operations and results. Words such as "may," "will," "expect,"
"believe," "anticipate," "estimate," "intends," "goal,"
"objective," "seek," "attempt," or variations of these or similar
words, identify forward-looking statements. These forward-looking
statements by their nature are estimates of future results only and
involve substantial risks and uncertainties, including but not
limited to risks associated with the uncertainty of future
financial results, additional financing requirements, development
of new products, our ability to complete our product testing and
launch our product commercially, the acceptance of our product in
the marketplace, the uncertainty of the laws and regulations
relating to cannabis, the impact of competitive products or
pricing, technological changes, the effect of economic conditions
and other uncertainties detailed from time to time in our reports
filed with the Securities and Exchange Commission, available at
www.sec.gov or www.eviolabs.com.
View source version on